Targeting cannabinoid agonists for inflammatory and neuropathic pain

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 951-965

  Cheng, Yuan ^a   Hitchcock, Stephen A ^a  

^a AMGEN INC   (United States)

Author keywords

Cannabinoid; CB1 receptor; CB2 receptor; Inflammatory pain; Neuropathic pain

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADL 01 0763 1; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOR; CANNABIS; DEXANABINOL; GW 405833; GW 842166; INDOLE DERIVATIVE; JWH 051; JWH 056; JWH 151; L 759633; MORPHINE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; PRS 211375; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CANCER PAIN; CATALEPSY; CLINICAL TRIAL; CONCENTRATION LOSS; DOSE RESPONSE; DROWSINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPOTHERMIA; LOCOMOTION; NEUROPATHIC PAIN; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VERTIGO; XEROSTOMIA;

ANALGESICS; ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION; NEURALGIA; NEURITIS; PAIN MEASUREMENT; PAIN, INTRACTABLE; PROSPECTIVE STUDIES; RATS; RECEPTOR, CANNABINOID, CB2; RECEPTORS, DRUG; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 34447542824     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.951     Document Type: Review

References (77)

1. GAONI Y, MECHOULAM R. Isolation, structure, and partial synthesis of an active constituent of Hashish. J. Am. Chem. Soc. (1964) 86:1646-1647.
2. MUNRO S, THOMAS KL: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
3. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564.
4. HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
5. DIAZ-LAVIADA I, RUIZ-LLORENTE L: Signal transduction activated by cannabinoid receptors. Mini-Rev. Med. Chem. (2005) 5:619-630.
6. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science (1992) 258:1946-1949.
7. HANUS I, GOPHER A, ALMOG S, MECHOULAM R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. (1993) 36:3032-3034.
8. MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous; 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
9. 1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. USA (1999) 96:5786-5790.
10. 2 receptors. Science (2005) 310:329-332.
11. MANZANARES J, JULIAN MD, CARRASCOSA A: Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. (2006) 4:239-257.
12. FOXA, BEVAN S: Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin. Investig. Drugs (2005) 14(6):695-703.
13. BURNS TI, INECK JR: Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann. Pharmacother. (2006) 40:251-260.
14. FRIDE E, PERCHUK A, HALL FS, UHI GR, ONAIVIES: Behavioral methods in cannabinoid research. Methods Mol. Med. (2006) 123:269-290.
15. 2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA (1999) 96(25):14228-14233.
16. 2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 93:239-245.
17. 2 receptor. Br. J. Pharmacol. (2006) 149: 145-154.
18. 2 cannabinoid receptors. Anasthesiology (2003) 99:955-960.
19. 2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 119:747-757.
20. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J. Phamacol. Exp. Ther. (2004) 308:446-453.
21. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA (2003) 100(18):10529-10533.
22. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. (2006) 23:1530-1538.
23. 2 cannabinoid receptor mediation of antinociception. Pain (2006) 122:36-42.
24. VALENZANO KJ, TAFESSE L, LEE G et al.: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48:658-672.
25. 2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 96:253-260.
26. 2-selective agonist, GW405833. Eur. J. Pharmacol. (2005) 528:65-72.
27. 2 receptor. Bioorg. Med. Chem. (1999) 7:2905-2914.
28. 2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain (2005) 118:327-335.
29. 2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. (2004) 20:2311-2320.
30. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. (2005) 22:371-379.
31. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. (2003) 3:62-67.
32. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA (2005) 102:3093-3098.
33. 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J. Neurophysiol. (2004) 92:3562-3574.
34. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. (2003) 17:2750-2754.
35. WOTHERSPOON G, FOX A, McINTYRE S, COLLEY S, BEVAN S, WINTER J: Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 135:235-245.
36. 1 receptors. Pain (1998) 75:111-119.
37. CALIGNANO A, LA RANA G, GIUFFRIDA A, PIOMELLI D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394:277-281.
38. 1 receptors inhibits mechanically evoked responses of spinal neurons in non-inflamed rats and rats with hindpaw inflammation. Eur. J. Neurosci. (2003) 18:2239-2243.
39. 1 agonist. Pain (2006) 124:175-183.
40. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. (1996) 278:989-999.
41. 2 cannabinoid receptors. Eur. J. Pharmacol. (2004) 505:1-9.
42. JOHANEK LM, SOMONE DA: Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a beat injury. Pain (2004) 109:432-442.
43. JOHANEK LM, HEITMILLER DR, TURNER M, NADER N, HODGES J, SIMONE D: Cannabinoids attenuate capsaicin-evoked hyeralgesia through spinal and peripheral mechanisms. Pain (2001) 93:303-315.
44. NACKLEY AG, SUPLITA RL, HOHMANN AG: A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 117:659-670.
45. FOX A. KESINGLAND, A. GENTRY C et al.: The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 92:91-100.
46. RUKWIED R, WATKINSON A, McGLONE F, DVORAK M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain (2003) 102:283-288.
47. 1 and unidentified receptors. Neuropharmacology (2005) 28: 1117-1129.
48. FRIDE E, FEIGIN C, PONDE DE et al.: (+)-Cannabidiol analogues which bind cannabinoid recetpors but exert peripheral activity only. Eur. J. Pharmacol. (2004) 506:179-188.
49. SELTZMAN HH: Structure and receptor activity for classical cannabinoids. Curr. Med. Chem. (1999) 6:685-704.
50. 2 receptor ligands. Mini-Rev. Med. Chem. (2005) 5:641-649.
51. 2 selective ligands. Curr. Med. Chem. (2005) 12:1217-1237.
52. PAVLOPOULOS S, THAKUR GA, NIKAS SP, MAKRIYANNIS A: Cannabinoid receptors as therapeutic targets. Curr. Pharm. Design (2006) 12:1751-1769.
53. ADAMS R, HARFENIST M, LOEWE S: New analogs of tetrahydrocannabinol. XIX. J. Am. Chem. Soc, (1949) 71:1624-1628.
54. 8-tetrahydrocannabinols. Bioorg. Med. Chem. (2003) 11(7):1397-1410.
55. LU D, MENG Z, THAKUR GA et al.: Adamantyl cannabinoids: a novel class of cannabinergic ligands. J. Med. Chem. (2005) 48:4576-4585.
56. PAPAHATJIS DP, NAHMIAS VR, ANDREOU T. FAN P, MAKRIYANNIS A: Structural modifications of the cannabinoid side chain towards C3-aryl and 1′,1′-cycloalkyl-1′-cyano cannabinoids. Bioorg. Med. Chem. Lett. (2006) 16:1616-1620.
57. GAREAU Y, DUFRESNE C, GALLANT M et al.: Structure-activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem. Lett. (1996) 6(2):189-194.
58. 2 receptor. Bioorg. Med. Chem. (2006) 14:2386-2397.
59. 2 receptor. Bioorg. Med. Chem. (2006) 14:247-262.
60. JOHNSON MR, MELVIN, LS: The discovery of nonclassical cannabinoid analgesics. In: Cannabinoids as Theraperutic Agents. Mechoulam R (Ed.), CRC Press, FL. USA (1986):121-145.
61. HOWLETT AC, JOHNSON MR, MELVIN LS, MILNE GM: Nonclassical cannabinoid analgesics inhibit adenylate cyclase: development ofa cannabinoid receptor model. Mol Pharmacol. (1988) 33:297-302.
62. HUFFMAN JW, PADGETT LW: Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Cur. Med. Chem. (2005) 12:1395-1411.
63. D'AMBRA TE, EISSENSTAT MA, ABT J et al.: C-attached aminoalkylindoles: potent cannabinoid mimetics. Bioorg. Med. Chem. Lett. (1996) 6(1):17-22.
64. HUFFMAN JW, DAI D, MARTIN BR, MARTIN BR, COMPTON DR: Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. (1994) 4:563-566.
65. WILEY JL, COMPTON DR, DAI D et al.: Structure-activity relationships of indole-and pyrrole-derived canabinoids. J. Pharmaccol. Exp. Ther. (1998) 285:995-1004.
66. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. (1996) 278:989-999.
67. 2 receptor. Curr. Pharm. Design (2000) 6:1323-1337.
68. 2 receptor agonists. Bioorg. Med. Chem. (2005) 13:89-112.
69. HYNES J, LEFTHERIS K, WU H et al.: C-3 amido-indole cannabinoid receptor modulators. Bioorg. Med. Chem. Lett. (2002) 12:2399-2402.
70. WROBLESKI ST, CHEN P, HYNES J et al.: Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J. Med. Chem. (2003) 46:2110-2116.
71. 2 inverse agoniscs. Lett. Drug Design Dis. (2006) 3:298-303.
72. ARMER R, WARNE P, WITHERINGTON J: Recent disclosures of clinical drug candidates. Drug News Perspect. (2006) 19(1):65-72.
73. 2 selective agonists. J. Med. Chem. (2006) 49:5947-5957.
74. FERRARINI PL, CALDERONE V, CAVALLINI T et al.: Synthesis and biological evaluation of 1,8-nathphyridin-4(1H)-on-3-carbozamide derivatives as new ligands of cannabinoid receptors. Bioorg. Med. Chem. (2004) 12:1921-1933.
75. 1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem. (2006) 49:984-994.
76. 2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem. (2006) 49:70-79.
77. FARQUHAR-SMITH WP: Peripheral cannabinoid analgesia: neuronal and immune mechanisms. Rev. Analgesia (2005) 8:103-116.